Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study

AstraZeneca2 个研究点分布在 1 个国家目标入组 44 人开始时间: 2002年4月1日最近更新: 2007年12月18日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: AstraZeneca
入组人数: 44
试验地点: 2
主要终点: Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Signed informed consent, men and women aged ³18 to £65 years with diagnosis of OCD, at least 12 weeks of treatment with SSRI or clomipramine

排除标准

•Substance abuse or dependence, female patients who are pregnant, lactating or at risk of pregnancy, known intolerance or lack of response to quetiapine, use of antihypertensive medication with changing doses

结局指标

主要结局

Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.

次要结局

Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales.
Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.

研究者

发起方

AstraZeneca

申办方类型

Industry

研究点 (2)

Loading locations...

相似试验

已完成

4 期

Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood DysregulationSubstance Use DisordersMood DisordersBipolar Disorder

NCT02845453Boston Medical Center24

已完成

3 期

Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress DisorderPost-Traumatic Stress Disorder

NCT00306540AstraZeneca90

已完成

4 期

An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine DependenceCocaine DependenceBipolar Disorder

NCT00223210University of Texas Southwestern Medical Center100

已完成

3 期

Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar DepressionBipolar Depression

NCT01256177AstraZeneca361

已完成

3 期

Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar DepressionBipolar Disorder

NCT00083954AstraZeneca530